Pablo Ruiz-Ramon, MD
Nephrology · Temple Terrace, FLNPI 1598728537
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,406 of the $6,125 with a category attached, or 88.3%. It is spread thinly across 30 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations.
Across 234 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- AstraZeneca$750
- Amgen$599
- Bayer$591
- Aurinia Pharma U.S., Inc.$471
- Travere Therapeutics, Inc.$251
- plus $2K from 24 others
Across 85 payments — averaging $14,183 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$713K
- AstraZeneca$253K
- Vertex$132K
- Travere Therapeutics, Inc.$56K
- Bayer$23K
- Boehringer Ingelheim$17K
- plus $11K from 2 others
What the payments were for
- Food & beverage$5,40688%
- Education$71912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 26 | $1,011 |
| AstraZeneca(2 entities) | 39 | $750 |
| Amgen(2 entities) | 25 | $599 |
| Bayer | 24 | $591 |
| Aurinia Pharma U.S., Inc. | 11 | $471 |
| Travere Therapeutics, Inc. | 8 | $251 |
| Calliditas Therapeutics US Inc. | 10 | $219 |
| Fresenius USA Marketing, Inc. | 10 | $217 |
| Akebia Therapeutics Inc | 12 | $211 |
| OPKO Pharmaceuticals, LLC | 11 | $202 |
| Mallinckrodt Hospital Products Inc. | 8 | $189 |
| Daiichi Sankyo Inc. | 9 | $189 |
| Mallinckrodt Enterprises LLC | 5 | $163 |
| Ardelyx, Inc. | 2 | $143 |
| Novartis | 6 | $139 |
| Foundation Fusion Solutions, LLC | 1 | $129 |
| ANI Pharmaceuticals, Inc. | 4 | $111 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $111 |
| Novo Nordisk | 3 | $64 |
| Veloxis Pharmaceuticals, Inc. | 1 | $54 |
| Boehringer Ingelheim | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 3 | $48 |
| Vifor Pharma, Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| GSK | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Cormedix Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$478
- LUPKYNIS$241
- XPHOZAH 30 MG$125
- Kerendia$121
How this compares
$6,125 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 139 | $175,824 |
| VelphoroSucroferric Oxyhydroxide | 39 | $117,755 |
| KerendiaFinerenone | 58 | $65,141 |
| JardianceEmpagliflozin | 63 | $59,314 |
| OzempicSemaglutide | 18 | $32,100 |
| Lanthanum Carbonate | 18 | $20,883 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $17,445 |
| Paricalcitol | 99 | $15,939 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 25 | $12,749 |
| EdarbiAzilsartan Medoxomil | 16 | $11,699 |
| MounjaroTirzepatide | 13 | $11,651 |
| DapagliflozinDapagliflozin Propanediol | 16 | $11,629 |
| AliskirenAliskiren Hemifumarate | 37 | $9,801 |
| Eplerenone | 105 | $7,790 |
| Potassium Citrate ErPotassium Citrate | 31 | $5,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $750 | $193,269155 claims |
| Fresenius USA Marketing, Inc.Velphoro | $217 | $117,75539 claims |
| BayerKerendia | $591 | $65,14158 claims |
| Boehringer IngelheimJardiance | $50 | $59,31463 claims |
| Novo NordiskOzempic | $64 | $32,10018 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $29 | $24,44941 claims |
| Lilly USA, LLCMounjaro | $23 | $11,65113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.
Other nephrology in Temple Terrace
- Jason RothschildTemple Terrace$413K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.